Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 17;15(10):1277. doi: 10.3390/ph15101277

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Three pathways of targeted therapeutic agents for pulmonary artery hypertension. Current therapeutic agents are targeted at correcting endothelial dysfunction by inhibiting the endothelin pathway and enhancing the prostacyclin or nitric oxide (NO) pathway. PGI2: prostaglandin I2; ETRA: endothelin A receptor; ETRB: endothelin B receptor; eNOS: endothelial isoform of nitric oxide synthase; sGC: soluble guanylate cyclase, PDE5: phosphodiesterase type 5, cAMP: cyclic adenosine monophosphate; cGMP: cyclic guanosine monophosphate.